Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A2 | O95436 | 11/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ADCYAP1R1 | P41586 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL268098 | 0.88 | CTDSP1 (0.37) | MAPTRAB9ALMNAPOLBNPC1 | |
| SCHEMBL268493 | 0.88 | RAB9A (0.44) | MAPTRAB9ALMNAGAAPOLB | |
| SCHEMBL270113 | 0.87 | NPC1 (0.42) | MAPTRAB9ALMNAGAANPC1 | |
| SCHEMBL269451 | 0.87 | GUSB (0.41) | MAPTRAB9APOLBNPC1NFKB1 | |
| SCHEMBL267434 | 0.85 | MAPT (0.42) | MAPTRAB9AGAAPOLBNPC1 | |
| SCHEMBL266176 | 0.83 | SLC34A2 (0.37) | SLC34A2MAPTRAB9APOLBNPC1 | |
| SCHEMBL266941 | 0.83 | SLC34A2 (0.43) | SLC34A2MAPTRAB9ALMNANPC1 | |
| SCHEMBL268193 | 0.83 | SLC34A2 (0.48) | SLC34A2MAPTSMN1; SMN2ADCYAP1R1ALDH1A1 | |
| SCHEMBL273734 | 0.83 | SLC34A2 (0.48) | SLC34A2MAPTSMN1; SMN2ADCYAP1R1ALDH1A1 | |
| SCHEMBL266125 | 0.79 | HPGD (0.39) | MAPTRAB9ALMNAGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134015-B2 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20060217426-A1 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-28 | — | — | US | disclosed |
| EP-1614676-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217426-A1 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | SLC10A6, SLC7A1, SLC10A1 | SLC34A2 6/4885MAPT 4195/4885RAB9A 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.